Cathie Wood's Called It Years Ago – Illumina Is the Must-Own Personalized Biotech Stock
Cathie Wood has championed genomics for years while the rest of the market chased the next flashy therapy. The personalized biotech revolution isn't just about editing genes. It starts with reading them at scale.
Precision medicine – the practice of tailoring treatments to a patient's unique genetic profile – is exploding. Grand View Research projects the market will expand from $87.5 billion in 2023 to $249.24 billion by 2030, a 16.3% CAGR. At the center sits Illumina (ILMN), the company that sequences the data powering it all. Smart investors who listened to Wood early are now seeing why ILMN quietly leads the pack.
The Sequencing Backbone Smart Investors Can't Ignore
Illumina doesn't sell cures. It sells the picks and shovels. Its next-generation sequencing (NGS) platforms generate the raw genetic data that drugmakers, hospitals, and AI models need to deliver truly personalized care.
MarketsandMarkets forecasts the global NGS market will grow from $14.94 billion in 2025 to $29.53 billion by 2030 at a 14.6% CAGR. Illumina still commands the high-throughput segment that drives the majority of clinical volume.
Let's look at the numbers. In its Q4 earnings release, Illumina reported revenue of $1.16 billion, up 5% year-over-year. Ex-China, revenue rose 8%. Clinical consumables – tests used in hospitals for oncology and rare diseases – jumped 20% outside China. For full-year 2025, revenue totaled $4.34 billion (flat overall, but ex-China up 2%). That's steady execution in a year when many biotech tools companies struggled.
Illumina's 2026 Breakthroughs Are Already Here
2026 is shaping up as the year Illumina turns the corner. The company guided for full-year revenue of $4.5 billion to $4.6 billion – 4% to 6% growth. That includes a 1.5% to 2% lift from its recent SomaLogic acquisition, which adds multi-omics capabilities.
In January, Illumina launched the Billion Cell Atlas – the world's largest genome-wide genetic perturbation dataset. The first tranche already covers one billion cells; the full project will reach five billion over three years. Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) signed on as launch partners to train AI models for faster drug discovery.
Then, in February, the company unveiled an 18-month NovaSeq X roadmap: 40% higher output to 35 billion reads per run and the first-ever Q70 quality scores. That's a fancy way of saying faster, cheaper, more accurate sequencing for oncology and genetic disease testing.
How Illumina Stacks Up
Thermo Fisher Scientific (TMO) offers broader life-science tools but trails in pure high-throughput NGS share. Pacific Biosciences dominates long-read sequencing yet holds far less clinical volume. Illumina's installed base and consumables-driven model – high-margin recurring revenue – deliver the clearest leverage to the precision-medicine boom.
ARK Genomic Revolution ETF (ARKG) still holds ILMN at 4.44% of assets and 1.38% of assets in ARK Innovation ETF (ARKK), underscoring Wood's conviction that sequencing remains foundational.
Key Takeaway
When all is said and done, Illumina isn't the flashiest name in biotech, but it may prove the most durable winner. Granted, China exposure remains a one-point headwind in 2026, and competition in long-read tech is real.
Still, with clinical momentum accelerating and AI datasets scaling, ILMN offers retail investors direct, lower-risk exposure to the genomic revolution Cathie Wood spotted years ago. For patient investors seeking the backbone of personalized medicine, Illumina is the stock that keeps delivering the data – and the growth.